Patients With Dermatomyositis/Polymyositis During Pregnancy

Fasoulakis N. Zacharias¹; Galanopoulos G. Nikolaos, PhD²; Kontomanolis N. Emmanuel, PhD³

¹Doctor in Obstetrics and Gynaecology, Democritus University of Thrace, Alexandroupolis, Greece
²Clinical Director in Rheumatology, Democritus University of Thrace, Alexandroupolis, Greece
³Assistant Professor in Obstetrics and Gynaecology, Democritus University of Thrace, Alexandroupolis, Greece

ABSTRACT

Dermatomyositis (DM) and polymyositis (PM) belong to the group of inflammatory muscle diseases characterized by inflammation of the muscles and represent immune-mediated syndromes secondary to defective cellular immunity with an incidence in the United States that ranges from 0.5-8.4 cases per million population and it is more common within the black population. Evidence support the idea of a T-cell–mediated cytotoxic process directed against unidentified muscle antigens with the factors triggering a T-cell–mediated process being still unclear. Due to common symptoms and laboratory tests (increased levels of muscle enzymes), DM and PM are usually studied together. The most common symptom of those diseases is symmetric muscle weakness, pain and tenderness. DM also appears to have skin manifestations (93%) not observed in PM, a characteristic that also makes it easier to diagnose (in addition to the other diagnostic criteria that involve abnormal electromyograph, elevated serum levels of CK and muscle biopsy).1-4

Regarding pregnant patients affected with DM/PM, important individual issues arise as: (A) Do female patients with DM/PM successfully complete pregnancy, giving birth to healthy infants or is there high risk of complications for both mother and fetus? (B) Is there a connection between activity of DM/PM and high risk of complications during gestation? (C) Does pregnancy increase the risk of DM/PM activation? (D) Does pregnancy increase the risk of DM/PM relapse during or right after gestation? After our attempt to answer these questions, we will refer to the treatment of the disease during pregnancy and the effect it could have on the completion of pregnancy.

KEYWORDS: Dermatomyositis; Polymyositis; Pregnancy; CPK; Immunoglobulin; Prednisolone.

ABBREVIATIONS: DM: Dermatomyositis; PM: polymyositis; CPK: Creatinane Phosphokinase.

INTRODUCTION

Dermatomyositis (DM) and polymyositis (PM) belong to the group of inflammatory muscle diseases characterized by inflammation of the muscles and represent immune-mediated syndromes secondary to defective cellular immunity with an incidence in the United States that ranges from 0.5-8.4 cases per million population and it is more common within the black population. Evidence support the idea of a T-cell–mediated cytotoxic process directed against unidentified muscle antigens with the factors triggering a T-cell–mediated process being still unclear. Due to common symptoms and laboratory tests (increased levels of muscle enzymes), DM and PM are usually studied together. The most common symptom of those diseases is symmetric muscle weakness, pain and tenderness. DM also appears to have skin manifestations (93%) not observed in PM, a characteristic that also makes it easier to diagnose (in addition to the other diagnostic criteria that involve abnormal electromyograph, elevated serum levels of CK and muscle biopsy).1-4
the completion of pregnancy.

DERMATOMYOSITIS AND POLYMYOSITIS DURING PREGNANCY

A. Do Female Patients with DM/PM Successfully Complete Pregnancy, Giving Birth to Healthy Infants or is there High Risk of Complications for Both Mother and Fetus?

Given the international literature, a wide number of studies have focused on female patients with DM/PM where the symptoms appeared during adolescence, teenage or adult life:

1) Regarding patients contracting the disease during adolescent or teenage years.

   In 1992 Pinheiro Gda et al published a case report of a woman in her 37th week of gestation with adolescent DM who due to fetal distress underwent urgent cesarean section giving birth to a healthy infant. Both the mother and the child were healthy upon reexamination eight months later.

   The progress of the first gestation of a 22-year-old woman with adolescent DM was first described by Madu et al while she was being treated with low dosage corticosteroids (5 mg prednisolone every two days). The examination of the fetus in 20th week of gestation was normal. An ultrasound test with Doppler analysis was conducted in 34th, 36th and 37th week showing no abnormalities. The patient presented exacerbation of skin rash on the 39th week and labor induction with intravaginal prostaglandin infusion which led to spontaneous rupture of the membranes, causing childbirth. The infant, weighting 2790 gr, and the mother were both in good condition.

2) Regarding female patients whose disease was first diagnosed with DM in adult life the conclusions are contradictory with reports advocating good pregnancy outcome, or correlation between disease activity and adverse outcome, or even initiation of the disease during pregnancy or after childbirth.5-10

   In most cases the gestation was successfully completed with only a small number of complications. In 1984, a group of 18 women with DM/PM was studied by Gutierrez et al. Ten pregnancies involving 7 women were monitored. Concerning 4 of these women the start of the gestation coincided with the beginning of the disease while with the other 3, the disease was dormant and an outbreak sometime during pregnancy occurred. Fifty-five percent of these cases ended in fetal death whilst 50% of the remaining gestation was premature terminated.

   In contrast, in 1992 Ohno et al presented two women with active DM who became pregnant, giving birth without complications to healthy infants.

   In the study of Missumi et al in 2015 regarding the progress of gestation during active DM/PM, from a total of 98 women (60 women with DM and 38 with PM) 78 pregnancies were monitored and studied between June 2011 and June 2012. The study resulted in good pregnancy outcomes (except 1 intrauterine reactivation, 1 diabetes mellitus, 1 hypertension, 1 disease reactivation, 1 hypothyroidism and 2 fetal losses) with patients developing dermatomyositis during pregnancy and 4 during the post-partum period, with good control after corticoid and immunosuppressive therapy. Therefore, the authors concluded that pregnant patients do not seem to be connected to worse prognosis or high risk for either the mother or the fetus, while the disease, either during pregnancy or the postpartum, had good outcome after therapy.

B. Is There a Connection Between Activity of DM/PM and High Risk of Complications During Gestation?

   A research of the international literature proves a possible correlation between connective tissue diseases and complications during gestation. In 1998, Skomsvoll et al presented a study were the births recorded in the medical birth registry of Norway in the period 1967-1995 were studied for obstetrical complications and interventions at delivery. The authors reported 72 pre-mature births, 30 pre-eclampsia cases, 42 low birth weight, reporting a possible connection between the outcomes and active disease.

   Other studies also reported a more specific association between the activity of the DM/PM and the increased risk of complications during pregnancy.12,14 However, complications of pregnancy in women whose disease was in remission were also reported15 as well as lack of correlation between disease activity and progression of pregnancy.8,16 Even though the results seem more satisfying than worrying, more studies need to be conducted to reach safe conclusions considering the connection of complications during pregnancy to DM/PM.

C. Does Pregnancy Increase the Risk of DM/PM Activation?

   In 2014 Pinal-Fernandez et al reported 102 gestations out of 51 women with inflammatory muscle disease (41 with DM and 10 with PM) diagnosed during 1983-2013. From these, 14 pregnancies regarding 8 women took place during activity of the disease. Seven women showed clinical improvement whilst exacerbation of the disease occurred in 5 pregnancies with 2 women. In other women, the disease remained inactive during pregnancy. No myopathy in any pregnancy was observed. Thus, the researchers concluded that pregnant patients with DM/PM are not accompanied by an unfavorable prognosis for the mother or the fetus, and that approximately on 50% of the patients the disease showed improvement during pregnancy.

D. Does Pregnancy Increase the Risk of DM/PM Relapse During or Right After Gestation?

   The research of Missumi et al in 2015 resulted in 2 patients developing the disease during pregnancy and 4 women (2 with
DM and 2 with PM) after childbirth.

Similarly, Park et al.\(^{18}\) reports the appearance of a typical DM’s skin rash and intense muscle weakness in the 12\(^{th}\) week of pregnancy in a woman 22 years of age while Koffteridis et al.\(^{22}\) presented a patient with acute appearance of DM combined with rhabdomyolysis in the 14\(^{th}\) week of pregnancy resulting in miscarriage of the fetus. Also, Ohno et al.\(^{19}\) described a woman with the appearance of DM in the third trimester of pregnancy. In the second pregnancy, the possible outbreak of the DM was avoided with oral use of 0.3 mg/kg body weight prednisolone per day. Both pregnancies were successfully completed with the mother and the newborn developing no health problems.

The case of a 30 year old female that developed muscular pain and muscle weakness combined with facial, elbow and knee skin rash, while pregnant with triplets (confirmed by ultrasound) in 8\(^{th}\) week of gestation was presented by Toyjo et al.\(^{20}\) The laboratory tests revealed increased creative phosphokinase levels (CPK serum) and anti-Jo-1 antibodies. A skin biopsy showed edema in the superficial layer of the dermis and aequous alteration in the stratum basale of the epidermis. Diagnosis of DM was then confirmed and oral treatment with 80 mg of pre-dnisolone daily without observation improved the symptoms. All the embryos died. Their death was linked to DM.

Of interest is the case of a 27-year-old woman described by Pasrija et al.\(^{21}\) During the third trimester of pregnancy, the patient showed a sudden lilac rash and Gorton papules on the dorsal surface of the upper hands, weakness of the proximal muscles and palpitations combined with high creatinine phosphokinase (CPK) serum levels. Electromyography in the left deltoid muscle was conducted, showing findings compatible with myopathy while biopsy of the right deltoid muscle revealed the presence of lymphocytic inflammatory infiltrates and necrotic muscle fibers. The patient started administration of 8 mg dexamethasone intramuscularly twice daily combined with hydroxychloroquine. The muscle symptoms retreated immediately but not the skin rash. The patient experienced episodes of dyspnea and intense palpitation. In the 33\(^{rd}\) week of pregnancy and echocardiogram revealed generalized hypokinesia on the wall of the left ventricle and 45% ejection fraction. The Doppler examination in the 36\(^{th}\) week showed high resistance index (resistance index=0.6) in the left uterine artery. In the 37\(^{th}\) week a healthy infant weighing 2,500 g by spontaneous vaginal delivery followed.

Relapse of DM shortly after birth or miscarriage has also been reported. In the study of Vancsa et al.\(^{12}\) one out of 9 patients with DM/PM, developed DM during the 3\(^{rd}\) trimester of gestation.

In the study of Kaddour et al.\(^{14}\) in 9 pregnancies with an active DM/PM, an outbreak was reported in one woman 10 days after childbirth.

The Kanoh et al.\(^{22}\) also report the case of a female who developed DM after childbirth of a healthy infant. A similar case was described by Lee et al.\(^{23}\)

The Yassaee et al.\(^{14}\) described in 2009 the case of a 38 year old woman that revealed cutaneous symptoms of DM 4 days after spontaneous abortion (facial erythema, Gorton papules on both hands and elbows and telangiectasias) but without muscle participation or increase of CPK levels. The skin biopsy was compatible with DM.

**Treatment during Gestation**

In 2015 Ochiai et al.\(^ {25}\) reported a case of a patient with rheumatoid arthritis and interstitial pneumopathy that developed amyotrophic dermatomyositis during pregnancy, treated with pre-dnisolone that improved skin symptoms and interstitial pneumopathy as well as giving birth to a healthy infant in 35\(^{th}\) week.

In 2007, Williams et al.\(^ {26}\) described a case of a young first time pregnant woman where DM appeared in the first weeks of pregnancy. The administration of intravenous immunoglobulin (1 g/kg month body weight for two consecutive days) was accompanied by a decline of symptoms in conjunction with the reduction of CPK levels. The pregnancy was completed normally for both mother and fetus (healthy infant weighing 3.657, 5 g).

Likewise, in 2008 described a case of a 31-year-old woman that developed fever, muscle weakness, skin rash (peri orbital and Gorton papules) as far as joint pain and CPK increase. Prednisolone was administered (60 mg/day) orally with regression of clinical events and reducing serum levels CPK. This dosage was progressively reduced to 35 mg/day. The pregnancy evolved satisfactorily but the ultrasound scan showed intrauterine growth restriction.

In the 35\(^{th}\) week cesarean section was conducted. The infant had lower body weight (1502 g), but was in good condition. In contrast, the mother lost consciousness during spinal anesthesia and had to be intubated. The extubation was difficult because of the presence of weakness of the respiratory muscles. Intravenous immunoglobulin was administered at 20 g/day for 5 consecutive days in combination with 30 mg/day prednisolone orally. The skin rash and muscle weakness subsided, the serum CPK levels decreased significantly but without full restoration of the respiratory muscles. Rehabilitation program for the respiratory muscles followed, leading to a reduction of the partial pressure of carbon dioxide (PaCO\(_2\)) and successful extubation attempt. The patient left the hospital in satisfactory condition only treated with low doses of pre-dnizolone.\(^ {27}\)

**CONCLUSION**

Dermatomyositis (DM) and Polymiositis (PM) are inflammatory myopathies of unknown etiology but with common symptoms. When the symptoms occur during pregnancy, the disease represents a challenge for both the patient and the obstetrician in order to follow therapy with no effect for the mother and...
especially the fetus. Most evidence support that the appropriate treatment with immunosuppressants allows a normal pregnancy without major problems and with no further risk for post-partum relapse. However, follow-up studies need to confirm such claims and to provide clear evidence on acute exacerbation during pregnancy.

AUTHORS CONTRIBUTIONS

All authors participated in writing the paper and approved the final version of the manuscript.

CONFLICTS OF INTEREST

The authors declare that they have no competing interests.

COMPLIANCE WITH ETHICAL STANDARDS

This article does not contain any studies with human participants or animals performed by any of the authors.

REFERENCES


